Preregistration
Selective reporting in trials of psychedelic drugs for mental disorders
Abstract
Outcome reporting bias and publication bias in randomized controlled trial of esketamine, psilocybin and MDMA for mental health condition
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Keywords
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
Related research
ArticleMDMA
Chemsex drugs: More than ghb, mephedrone and methamphetamine?
ArticlePsilocybin
Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.
ArticleKetamine